"Eos" is the Greek word for dawn. Newleos is chasing a new one - for the one in eight people on earth living with a mental illness.
Above: the logo of a company whose entire pipeline was, technically, somebody else's homework.
In a lab-and-office stretch of Boston, a 27-person company is running four clinical-stage drug programs at once. That is an unusual ratio. Most biotechs this small have one shot on goal and a prayer. Newleos has four - generalized anxiety, social anxiety, substance use cravings, and cognitive impairment - and it didn't invent a single one of them.
Newleos Therapeutics launched in February 2025 with an oversubscribed $93.5 million Series A and a contrarian premise: that the most promising medicines for the brain might already exist, sitting unloved on a larger company's shelf. The drugs were Roche's. Roche walked away from them. Newleos walked toward them.
Anxiety, substance use disorders, and cognitive impairment affect a staggering share of humanity. The standard responses - SSRIs that take weeks to work, benzodiazepines that sedate and create dependence - have not fundamentally changed in a generation. They blanket the whole brain when the problem is often a single circuit.
That's the tension Newleos exists inside: the science of the brain has moved fast, but the medicine cabinet hasn't. Pharmaceutical giants have spent the last decade quietly retreating from neuroscience, deciding it was too slow, too risky, too hard to measure. Good programs got shelved not because they failed, but because they no longer fit a strategy.
Newleos looked at that retreat and saw inventory. Four oral small molecules, each aimed at a precise neuropsychiatric mechanism, each already advanced enough to enter or re-enter the clinic. The hard, expensive early science was done. What was missing was a company willing to believe in it.
Newleos was co-founded by the Longwood Fund alongside a roster of CNS veterans - David Donabedian, William Martin, Federico Bolognani, Christoph Westphal, Miguel Sobral, and Rob Hadfield. The wager was not on a single molecule but on a method: combine clinically de-risked assets with people who have actually shepherded brain drugs through trials before.
In October 2025, the company brought in Timothy Noyes as President and CEO - a 30-year biopharma operator who had already taken two companies, Aerovate and Proteon, public. Donabedian, the founding CEO, stepped into an advisory seat. The message to investors was unsubtle: this is a team built to execute, not to discover.
The pipeline is a tidy alphabet of receptor targets. The lead program, NTX-1955, is designed to modulate GABA signaling specifically in the amygdala - the brain's fear circuit - with the goal of calming anxiety without dulling everything else. It's a small idea with big implications: an anxiety drug that doesn't sedate you.
Targets the γ1 subunit enriched in the amygdala to reduce generalized anxiety while sparing networks tied to sedation and dependence.
In development for social anxiety disorder, a condition with few targeted pharmacological options.
Aimed at the cravings that drive substance use disorders, a mechanism drawing intense industry interest.
Targets cognitive impairment in rare neurodevelopmental conditions such as dup15q syndrome.
Newleos emerges from stealth with an oversubscribed $93.5M Series A and four ex-Roche neuropsychiatric programs.
Leadership team expands and a clinical advisory board is announced to support the key neuropsychiatry programs.
Timothy Noyes, two-time biotech IPO CEO, is named President & CEO; founder David Donabedian moves to advisor.
Company targets Phase 2 data across all four assets - on roughly a 2.5-year runway from the Series A.
Bars are illustrative of relative program emphasis, not clinical results. The real readouts come in 2027.
For a company built on the idea of rescuing shelved drugs, the investor list does a lot of persuading. Goldman Sachs Alternatives led the round, joined by Novo Holdings, the Longwood Fund, DCVC Bio, and Arkin Bio Capital. "Oversubscribed" is the polite biotech term for more interest than there was room - rare in a stretch when neuroscience funding has been hard to find.
The real proof, of course, won't come from a cap table. It will come in fall 2027, when the company aims to have Phase 2 readouts on all four programs. Until then, the bet is on the team, the mechanisms, and the unfashionable idea that a good drug is a good drug regardless of who shelved it.
The name is not an accident. "Eos" was the Greek goddess of dawn, and Newleos means, more or less, "a new dawn." For a field where the standard of care has barely budged in decades, that framing is either marketing or a manifesto - and the company is betting it's the latter. The goal is medicines that work on precise mechanisms, with fewer of the side effects that make today's treatments a compromise patients tolerate rather than a solution they choose.
Return to that 27-person company running four clinical programs. The ratio still looks improbable - until you see the strategy underneath it. Newleos isn't trying to out-discover Big Pharma. It's trying to out-believe it: to take science that giants abandoned and prove the abandonment was a mistake of strategy, not of science.
If that works, the payoff is bigger than four drugs. It's a template - a way to rescue good medicine from the gap between what's scientifically promising and what's corporately convenient. Plenty of brilliant programs die in that gap every year. Newleos is one experiment in whether they have to.
The dawn metaphor will get tested in 2027, in trial data that doesn't care about names or narratives. Until then, Newleos is a clean, slightly contrarian idea wearing a lab coat: someone's leftovers might be exactly what millions of people have been waiting for.